Federal Register / Vol. 88, No. 247 / Wednesday, December 27, 2023 / Notices 89453 

performed on or after January 1, 2024 

through December 31, 2024. 

FOR FURTHER INFORMATION CONTACT: For 

clarification of content, please contact 

Mrs. Autumn King, Policy Analyst, 

Office of Government-wide Policy, 

Office of Asset and Transportation 

Management, at 803–944–6487, or by 

email at travelpolicy@gsa.gov. Please 

cite Notice of FTR Bulletin 24–03. 

SUPPLEMENTARY INFORMATION: GSA is 

required by statute to set the mileage 

reimbursement rate for privately owned 

automobiles (POA) as the single 

standard mileage rate established by the 

Internal Revenue Service (IRS). The IRS 

mileage rate for medical or moving 

purposes is used to determine the POA 

rate when a Government-furnished 

automobile is available and authorized 

and also represents the privately owned 

vehicle (POV) standard mileage 

reimbursement rate for official 

relocation. 

Finally, GSA conducts independent 

reviews of the cost of travel and the 

operation of privately owned airplanes 

and motorcycles on an annual basis to 

determine their corresponding mileage 

reimbursement rates. These reviews 

evaluate various factors, such as the cost 

of fuel, depreciation of the original 

vehicle cost, maintenance and 

insurance, state and Federal taxes, and 

consumer price index data. FTR 

Bulletin 24–03 establishes and 

announces the new CY 2024 POV 

mileage reimbursement rates for official 

temporary duty and relocation travel. 

This notice is the only notification to 

agencies of revisions to the POV mileage 

rates for official travel and relocation, in 

addition to the changes posted on GSA’s 

website at https://gsa.gov/mileage. 

Krystal J. Brumfield, 

Associate Administrator, Office of 

Government-wide Policy. 

[FR Doc. 2023–28563 Filed 12–26–23; 8:45 am] 

BILLING CODE 6820–14–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meetings 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), Department of 

Health and Human Services (HHS). 

ACTION: Notice of five AHRQ 

subcommittee meetings. 

SUMMARY: The subcommittees listed 

below are part of AHRQ’s Health 

Services Research Initial Review Group 

(IRG) Committee. Grant applications are 

to be reviewed and discussed at these 

meetings. Each subcommittee meeting 

will be closed to the public. 

DATES: See below for dates of meetings: 

1. Healthcare Effectiveness and 

Outcomes Research (HEOR) 

Date: February 7–8, 2024 

2. Healthcare Safety and Quality 

Improvement Research (HSQR) 

Date: February 7–8, 2024 

3. Health System and Value Research 

(HSVR) 

Date: February 13–14, 2024 

4. Healthcare Research Training (HCRT) 

Date: February15–16, 19, 2024 

5. Healthcare Information Technology 

Research (HITR) 

Date: February 29-March 1, 2024 

ADDRESSES: Agency for Healthcare 

Research and Quality (Virtual Review), 

5600 Fishers Lane, Rockville, Maryland, 

20857. 

FOR FURTHER INFORMATION CONTACT: (to 

obtain a roster of members, agenda or 

minutes of the non-confidential portions 

of the meetings.) 

Jenny Griffith, Committee 

Management Officer, Office of 

Extramural Research Education and 

Priority Populations, Division of Policy, 

Coordination and Analysis, Agency for 

Healthcare Research and Quality 

(AHRQ), 5600 Fishers Lane, Rockville, 

Maryland 20857, Telephone (301) 427– 

1557. 

SUPPLEMENTARY INFORMATION: In 

accordance with section 10 (a)(2) of the 

Federal Advisory Committee Act (5 

U.S.C. app. 2), AHRQ announces 

meetings of the above-listed scientific 

peer review groups, which are 

subcommittees of AHRQ’s Health 

Services Research Initial Review Group 

Committee. The subcommittee meetings 

will be closed to the public in 

accordance with the provisions set forth 

in 5 U.S.C. app. 2 section 10(d), 5 U.S.C. 

552b(c)(4), and 5 U.S.C. 552b(c)(6). The 

grant applications and the discussions 

could disclose confidential trade secrets 

or commercial property such as 

patentable material, and personal 

information concerning individuals 

associated with the grant applications, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Agenda items for these meetings are 

subject to change as priorities dictate. 

Dated: December 20, 2023. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2023–28506 Filed 12–26–23; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket Nos. FDA–2022–E–0931 and FDA– 

2022–E–0936] 

Determination of Regulatory Review 

Period for Purposes of Patent 

Extension; ZOKINVY 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or the Agency) has 

determined the regulatory review period 

for ZOKINVY and is publishing this 

notice of that determination as required 

by law. FDA has made the 

determination because of the 

submission of an application to the 

Director of the U.S. Patent and 

Trademark Office (USPTO), Department 

of Commerce, for the extension of 

patents which claims that human drug 

product. 

DATES: Anyone with knowledge that any 

of the dates as published (see 

SUPPLEMENTARY INFORMATION) are 

incorrect may submit either electronic 

or written comments and ask for a 

redetermination by February 26, 2024. 

Furthermore, any interested person may 

petition FDA for a determination 

regarding whether the applicant for 

extension acted with due diligence 

during the regulatory review period by 

June 24, 2024. See ‘‘Petitions’’ in the 

SUPPLEMENTARY INFORMATION section for 

more information. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. The https://

www.regulations.gov electronic filing 

system will accept comments until 

11:59 p.m. Eastern Time at the end of 

February 26, 2024. Comments received 

by mail/hand delivery/courier (for 

written/paper submissions) will be 

considered timely if they are received 

on or before that date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 


ddrumheller on DSK120RN23PROD with NOTICES1